scholarly journals Association Between microRNA-125a rs12976445 C>T Polymorphism and 18F-Fluorodeoxyglucose (18FDG) Uptake: Clinical and Metabolic Response in Patients with Non-Small Cell Lung Cancer

2016 ◽  
Vol 22 ◽  
pp. 4186-4192
Author(s):  
Zhina Zang ◽  
Wenhua Guan ◽  
Diansen Chen ◽  
Yan Han ◽  
Zhan Shi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Metabolic Response ◽  
Small Cell ◽  
Small Cell Lung ◽  
18F Fluorodeoxyglucose ◽  
18Fdg Uptake

Comparison of prognostic values of primary tumor and nodal 18F-fluorodeoxyglucose uptake in non-small cell lung cancer with N1 disease

2019 ◽  
Vol 29 (10) ◽  
pp. 5288-5297
Author(s):  
Chae Hong Lim ◽  
Seung Hyup Hyun ◽  
Seung Hwan Moon ◽  
Young Seok Cho ◽  
Joon Young Choi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Primary Tumor ◽  
Small Cell ◽  
Small Cell Lung ◽  
18F Fluorodeoxyglucose

scholarly journals Timing of Metabolic Response Monitoring During Erlotinib Treatment in Non-Small Cell Lung Cancer

2014 ◽  
Vol 55 (7) ◽  
pp. 1081-1086 ◽  
Author(s):  
M. H. van Gool ◽  
T. S. Aukema ◽  
E. E. Schaake ◽  
H. Rijna ◽  
R. A. Valdes Olmos ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Metabolic Response ◽  
Small Cell ◽  
Response Monitoring ◽  
Small Cell Lung

Administration of crizotinib via jejunostomy tube: A case report

2018 ◽  
Author(s):  
Lotte M Knapen
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Kinase Inhibitor ◽  
Metabolic Response ◽  
Small Cell ◽  
Small Cell Lung ◽  
Jejunostomy Tube ◽  
Anaplastic Lymphoma ◽  
Percutaneous Endoscopic Jejunostomy

Crizotinib is an orally available tyrosine kinase inhibitor, approved for treatment of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) rearrangement-positive non-small cell lung cancer (NSCLC). According to the product leaflet, crizotinib capsules should be swallowed whole, and should not be crushed, dissolved or opened. However, this manner of administration is not always possible. At present, literature is lacking regarding the absorption of crizotinib via percutaneous endoscopic jejunostomy (PEJ) tube. We report a case of a patient with ALK+ NSCLC who was administered crizotinib via PEJ tube. An adequate steady state crizotinib trough concentration was reached, resulting in a metabolic response. Safety for the caregiver was ensured since the administration of crizotinib was made without crushing or opening the capsule. This case supports the option for providing crizotinib via PEJ tube in patients who have ALK+ NSCLC and are unable to swallow whole capsules. This option might also apply to the administration of other ALK inhibitors. Keywords Crizotinib, ALK inhibitor, percutaneous endoscopic jejunostomy tube, pharmacokinetics, non-small cell lung cancer.

Sign in / Sign up

Export Citation Format

Share Document